PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31446643-5	2019	AZD9291 resistance was partially restored by combination of AZD9291 and crizotinib only in resistant cells overexpressing phospho-c-Met, which synergistically inhibited c-Met-mediated phosphorylation of the downstream targets ERK1/2 and AKT.	osimertinib	0-7	mitogen-activated protein kinase 3	Homo sapiens	226-232	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	mitogen-activated protein kinase 3	Homo sapiens	117-123	
33511016-8	2021	The combination of CP@NP-cRGD and AZD9291 significantly induces a higher rate of apoptosis, more G0/G1 phase arrest, and reduces proliferation of resistant cell lines by downregulation of p-ERK1/2 in vitro.	osimertinib	34-41	mitogen-activated protein kinase 3	Homo sapiens	190-196	
31446643-5	2019	AZD9291 resistance was partially restored by combination of AZD9291 and crizotinib only in resistant cells overexpressing phospho-c-Met, which synergistically inhibited c-Met-mediated phosphorylation of the downstream targets ERK1/2 and AKT.	osimertinib	60-67	mitogen-activated protein kinase 3	Homo sapiens	226-232